Effects of pulse-therapy on natural anticoagulant system of the endothelium in nonspecific aortoarteritis


Cite item

Full Text

Abstract

Aim. To investigate the influence of pulse-therapy on anticoagulant system of the endothelium in patients with nonspecific aortoarteritis.
Material and methods. Eleven patients (9 females and 2 males, mean age 33.4 ± 8.8 years, the disease duration 5.8 ± 5.7 years) with nonspecific aortoarteritis were examined. 9 patients had the third anatomic type of the disease with affection of the aortic arch and abdominal aorta vessels, 2 patients had the first anatomic type with isolated affection of the aortic arch. The patients received a standard three day course of pulse-therapy (PT) with glucocorticosteroids (GCS) (metipred in a dose 1000 mg/ day or dexametasone in a dose 2 mg/kg/day) with a single dose of cytostatic (CS) (cyclophosphamide in a dose 10 mg/kg b.w.) during the first infusion. Further PT consisted of monthly single infusion of GCS and CS in the above doses for 9 to 12 months. Examination of the patients was carried out before the treatment and on the treatment day 4 and 20 and follow-up month 3, 6 and 12. Estimation of clinical activity was carried out according to BVAS. Levels of protein C, S, antithrombin III were measured by ELISA in plasma. Activities of protein C, antithrombin III and plasminogen were determined by the optical assay with chromogenic substrates.
Results. Before the start of the treatment BVAS was 6.8 ± 4.3. During the follow-up mean scores of BVAS were significantly lower than before the pulse-therapy (2.7 ± 2.2; 2.5 ± 3.9; 3.1 ± 5.1;
1.8 ± 2.6 and 1.7 ± 1.7, respectively; p < 0.05). Prior to the treatment, a mean level of protein С was 86.6 ± 37.5% and range of its activity 175.2 ± 112.9%. On the fourth day after pulse-therapy a mean concentration of protein С increased (128.8 ± 29.0%; p < 0.05) while activity of protein С tended to a decrease on the 20th day (99.2 ± 17.6; p > 0.05). There were no significant differences in the levels of protein S, antithrombin HI and its activity, activity of plasminogen in the course of PT. Conclusion. PT has a good anti-inflammatory effect in the absence of unfavorable influence on anticoagulant system of the endothelium in patients with nonspecific aortoarteritis.

References

  1. Jennet J. С., Falk R. J., Andrassy К. et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthr. and Rheum. 1994; 37: 187-192.
  2. Cocwell P. Activation of endothelial cells in thrombosis and vasculitis. Scand. J. Rheumatol. 1997; 26: 145: 150.
  3. Blank M., Krause I., Goldkorn T. et al. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthr. and Rheum. 1999; 42: 1421-1432.
  4. Cadroy Y., Diquilou A., Dupouy D. et al. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Artgerioscler. Thromb. Vase. Biol. 1997; 17: 520-527.
  5. Bevilacqua M. P., Pober J. S., Majeau G. R. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endotheliun: characterization and comparison with the actions of interleukin-1. Proc. Natl. Acad. Sci. USA, 1986; 83: 4533-4537.
  6. Bevilacqua M. P., Pober J. S., Majeau G. R. et al. Interleukin 1 (IL1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 1984; 160: 618-623.
  7. Akazawa H., Ikeda U. Yamamoto K. et al. Hypercoagulable state in patients with Takayasu's arteritis. Thromb. Haemost. 1996; 75: 712-716.
  8. Pitzalis C., Koch A. The vascular endothelial system in the pathogenesis of inflammation and systemic rheumatic diseases: relation to the neuroendocrine system. Rheum. Dis. Clin. N. Am. 2000; 26: 765-773.
  9. Boumpas D. Т., Chrousos G. P., Wilder R. L. et al. Glucocorticoid therapy for immunomediated diseases: basic and clinical correlates. Ann Intern. Med. 1993; 119: 1198-1208.
  10. Zoorob R. J., Gender D. A. A different look at corticosteroids. Am. Fam. Physician. 1998; 58: 443-450.
  11. Deutz-Terlouw P. P., Battering L., van Wijngaarden A. et al. Two ELISA's for measurement of proitein S, and their use in the laboratory diagnosis of protein S deficiency. Clin. Chim. Acta 1989; 186: 321-334.
  12. Edgar P., Jennings I., Harper P. Enzyme linked immunosorbent assay for measuring antithrombin III. J. Clin. Pathol. 1989; 42: 985-
  13. Laszik Z., Mitro A., Taylor F. B. et al. Human protein С receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein С pathway. Circulation 1997; 96: 3633-3640.
  14. Stearns-Kurosawa D. J., Kurosawa S., Mollica J. S. et al. The endothelial cell protein С receptor augments proteins С activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA 1996; 93: 10212-10216.
  15. Mall V., Thomas К. В., Sauter S. et al. Effect of glucocorti- . coids, E. coli- and Erwinia L-asparaginase on hemostatic protein in children with acute lymphoblastic leukemia. Klin. Padiatr. 1999; 211: 205-210.
  16. Moffat G. J., Vik D. P., Boack D. et al. Complete structure of the murine C4b-binding protein gene and regulation of its expression by dexamethasone. J. Biol. Chem. 1992; 267: 20400- 20406.
  17. Баранов А. А., Насонов Е. Л., Шилкина Н. П. и др. Клиническое значение определения белка С и белка S у больных несцецифическим аортоартериитом. Тер. арх. 1996; 4: 50- 52.
  18. Esmon С. The protein С pathway. Crit. Care Med. 2000; 28: 44-48.
  19. Fatti L. M., Bottasso N., Invitti C. et al. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J. Endocrinol. Invest. 2000; 23: 145-150.
  20. Prandota J., Pankow-Prandota L., Kotecki L. Impaired activation of the fibrinolytic system in children with Henoch-Schonlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. Am. J. Ther. 2001; 8: 11-19.
  21. Huang L. Q., Whirtworth J. A., Chesterman С. В. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul. Fibrinolys. 1995; 6: 438-445.
  22. Bucciarelti P., Rosendaal F. R., Tripodi A. et al. Risk of venous thromboembolism and clinical manifestations in carries of antithrombin, protein C, protein S deficiency, or activated protein С resistance: a multicenter collaborative family study. Arterioscler. Thromb. Vase. Biol. 1999; 19: 1026-1033.
  23. Dickneite G., Leithduser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Ibid. 1566-1572.
  24. Frebelius S., Isacsson S., Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform ATB. Ibid. 1996; 16: 1292-1297.
  25. Prandota J., Pankow-Prandota L., Kotecki L. et al. Plasma proteinase inhibitor activity and hemostasis tests in children with nephrotic syndrome. Effect of prednizone alone and prednizone plus epsilon-aminocaproic acid treatment regimens: a preliminary report. Am. J. Ther. 2001; 8: 97-107.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies